TABLE 5.

Logistic regression models

Covariate	OR	95% CI	p-value
A: Willingness to participate in disease-modifying therapy trial
Agea	1.00	0.82–1.22	0.962
Male gender	1.15	0.80–1.66	0.464
IBD	0.64	0.42–0.98	0.038
Ursodiol treatment	1.22	0.84–1.75	0.293
Pruritus	1.62	1.09–2.40	0.017
Jaundice	0.34	0.19–0.61	<0.001
B: Willingness to participate in trial for symptom treatment
IBD	0.81	0.54–1.20	0.290
History of antibiotic treatment for cholangitis	1.26	0.86–1.84	0.243
Ursodiol treatment	1.16	0.80–1.66	0.436
Fatigue	1.22	0.78–1.91	0.388
Anxiety	1.02	0.69–1.53	0.913
Joint pain	0.97	0.61–1.54	0.886
Weakness	1.14	0.69–1.88	0.615
Abdominal pain	0.76	0.46–1.26	0.290
Pruritus	2.14	1.44–3.20	<0.001
Liver pain	1.49	0.93–2.37	0.097
Brain fog	1.16	0.74–1.83	0.512
Other pain	1.38	0.80–2.36	0.247
Nausea/vomiting	0.71	0.41–1.22	0.215
Anorexia	1.47	0.86–2.50	0.158
Night sweats	0.81	0.52–1.28	0.369

^aOrdinal variable: 18–25 y, 26–39 y, 40–59 y, >60 y.

Abbreviation: IBD, inflammatory bowel disease.